SPHK1 and colonic neoplasm: In addition to oxaliplatin, SphK1 also mediates the effects of 5-fluorouracil (5-FU) in colon cancer, since SphK1 knockdown or pharmacological inhibition enhanced sensitivity of colon cancer cells to 5-FU [64].